News Focus
News Focus
Post# of 257375
Next 10
Followers 1
Posts 115
Boards Moderated 0
Alias Born 10/18/2003

Re: Biopharm investor post# 2639

Friday, 06/25/2004 9:46:35 PM

Friday, June 25, 2004 9:46:35 PM

Post# of 257375
Generic Debate

As a pharmacist who has been working with generic drug substitution policies for many years, I see the benefits to our healthcare system that most generics have brought. Having said this, you must understand the requirements for an approved generic and the areas of physiology where the parameters for approval are not strict enough to ensure true bioequivalency.
In simple terms, the FDA allows for a +/- 20% variation in blood levels from brand to generic. The FDA states that the human body can not sense the difference of a 20% variation. In reality, the last time I checked, the average variation for submissions was ~4-5%. Unfortunately, most doctors will tell you that there are some drug classes (hormones, seizure meds, others) that are dosed so specifically that even a 4-5% swing may be enough to cause some untoward effects. Synthroid has always fallen under this umbrella.
I think this is why there is some very appropriate caution being used by professionals today regarding the rampant substitution that will occur in every pharmacy in America. Think about it logically. Why are there 12 different doses of Levoxyl, most dosed within 12.5mcg of each other! Small variations can matter!
Just my cautious two cents.
RPh

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today